Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review

View at publisher Summarise with VIRAT
Authors: Dong Hyun Kim, Seungah Cha, Youngil Koh, Ja Min Byun
Cited by: 0
References: 44

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

T-cell-directed immunotherapies, including chimeric antigen receptor T-cell therapy (CAR-T) and bispecific antibodies (BsAbs), have revolutionized the management of B-cell lymphomas, yet options after treatment failure remain limited. We reviewed four patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) after BsAb or CAR-T exposure, and performed a systematic literature review. Three patients had large B-cell lymphoma, one had follicular lymphoma. Two achieved durable remission, whereas two experienced early relapse or transplant-related mortality. The literature search identified six studies, evaluating allo-HSCT as salvage therapy after CAR-T failure or as consolidation following BsAb response. One-year overall survival exceeded 50% after CAR-T failure, with non-relapse mortality ranging from 20% to 33%. Prior CAR-T exposure did not clearly increase transplant-related toxicity, while allo-HSCT following BsAb therapy warrants vigilant infection monitoring and further prospective evaluation. Allo-HSCT may serve as an effective curative treatment after CAR-T or BsAb therapy, particularly in patients with controlled disease.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment CAR-T cell therapy research Hematopoietic Stem Cell Transplantation

Publication details

Journal / source
Leukemia & lymphoma/Leukemia and lymphoma
Volume
67
Issue
6
Pages
1317–1326
Publication date
22 March 2026
Language
EN